Escugen Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series B

  • Investors
  • 11

Escugen General Information

Description

Developer of antibody-drug conjugates designed for the treatment of cancer. The company utilises a proprietary linker-payload technology platform to couple topoisomerase I inhibitors with antibodies using stable, cleavable linkers, enabling the development of antibody-drug conjugates, monoclonal antibody drugs, trop-2-targeted therapies, CCR9-targeted conjugates, oncology therapeutics and precision medicine candidates, providing healthcare organizations with targeted therapies for cellular malignancies and immune diseases.

Contact Information

Website
www.escugen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5th Floor, Number 19, Lane 2777, Jinxiu East Road
  • Pudong New Area
  • Shanghai, 201206
  • China
+86 137
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 5th Floor, Number 19, Lane 2777, Jinxiu East Road
  • Pudong New Area
  • Shanghai, 201206
  • China
+86 137

Escugen Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Escugen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 14-May-2026 Completed Generating Revenue
8. Secondary Transaction - Private 14-May-2026 Completed Generating Revenue
7. Secondary Transaction - Private 07-Jun-2024 Completed Generating Revenue
6. Later Stage VC (Series A1) 27-Mar-2023 Completed Generating Revenue
5. Later Stage VC 23-Aug-2022 Completed Generating Revenue
4. Later Stage VC 23-Feb-2022 Completed Generating Revenue
3. Early Stage VC (Series A) 13-Oct-2021 Completed Generating Revenue
2. Early Stage VC 24-Aug-2020 $5.74M $10.8M Completed Generating Revenue
1. Seed Round 14-Mar-2017 $5.09M $5.09M Completed Startup
To view Escugen’s complete valuation and funding history, request access »

Escugen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Escugen Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Shenzhen Dongfang Huisheng Capital Management Corporation Minority
Suzhou Oriza Holdings Corporation Asset Manager Minority
Lotus Lake Ventures Venture Capital Minority
TopoScend Capital Growth/Expansion Minority
Shanghai Zhangjiang Science & Technology Venture Capital Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Escugen FAQs

  • When was Escugen founded?

    Escugen was founded in 2017.

  • Where is Escugen headquartered?

    Escugen is headquartered in Shanghai, China.

  • What is the size of Escugen?

    Escugen has 9 total employees.

  • What industry is Escugen in?

    Escugen’s primary industry is Drug Discovery.

  • Is Escugen a private or public company?

    Escugen is a Private company.

  • What is Escugen’s current revenue?

    The current revenue for Escugen is .

  • How much funding has Escugen raised over time?

    Escugen has raised $45.4M.

  • Who are Escugen’s investors?

    Shenzhen Dongfang Huisheng Capital Management, Suzhou Oriza Holdings Corporation, Lotus Lake Ventures, TopoScend Capital, and Shanghai Zhangjiang Science & Technology Venture Capital are 5 of 11 investors who have invested in Escugen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process